Alzheimer’s disease: from molecular pathogenesis to innovative therapies

References

• Papers of special note have been highlighted as:
   Google Scholar
• of interest
   Google Scholar
• of considerable interest
   Google Scholar
• Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Neurology 56, 11541166 (2001).
   Web of Science ®Google Scholar
• Important article from an American Academy of Neurology Committee gives the practice parameters of pharmacological treatment of dementia on the basis of the review of a very large number of published studies.
   Google Scholar
• Reisberg B, Doody R, Stoffer A et al. Memantine in moderate-to-severe Alzheimers disease. N. Engl. J. Med. 348(14), 13331341 (2003).
   Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 297, 353356 (2002).
   Web of Science ®Google Scholar
• Shows how the knowledge of the role of amyloid in the pathogenesis of Alzheimers disease can lead to new treatment modalities.
   Google Scholar
• McLean CA, Cherny RA, Fraser FW et al. Soluble pool of A amyloid as a determinant of severity of neurodegeneration in Alzheimers disease. Ann. Neurol. 46(6), 860866 (1999).
   Web of Science ®Google Scholar
• Koistinaho M, Ort M, Cimadevilla JM et al. Specific spatial learning deficits become severe with age in -amyloid precursor protein transgenic mice that harbor diffuse -amyloid deposits but do not form plaques. Proc. Natl Acad. Sci. USA 98(25), 1467514680 (2001).
   Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416(6880), 535539 (2002).
   Web of Science ®Google Scholar
• Sisodia SS, St George-Hyslop PH. - Secretase, Notch, A and Alzheimers disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281290 (2002).
   Google Scholar
• Dovey HF, John V, Anderson JP et al. Functional gamma-secretase inhibitors reduce -amyloid peptide levels in brain. J. Neurochem. 76, 173181 (2001).
   Web of Science ®Google Scholar
• Takasugi N, Tomita T, Hayashi I et al. The role of presenilin cofactors in the gammasecretase complex. Nature 422(6930), 438441 (2003)
   Web of Science ®Google Scholar
• Golde TE, Younkin SG. Presenilins as therapeutic targets for the treatment of Alzheimers disease. Trends Mol. Med. 6, 264269 (2001).
   Google Scholar
• Esler WP, Wolfe MS. A portrait of Alzheimer secretases new features and familiar faces. Science 293, 14491454 (2001).
   Web of Science ®Google Scholar
• Recent comprehensive review on the complex features of secretases.
   Google Scholar
• Ni CY, Murphy MP, Golde TE et al. - secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294, 21792181 (2001).
   Web of Science ®Google Scholar
• Golde TE. Alzheimers disease therapy: can the amyloid cascade be halted? J. Clin. Invest. 111(1), 1118 (2003).
   Google Scholar
• Petit A, Bihel F, Alves da Costa C et al. New protease inhibitors prevent -secretasemediated production of A40/42 without affecting Notch cleavage. Nat. Cell. Biol. 3, 507511 (2001).
   Google Scholar
• Luo Y, Bolon B, Kahn S et al. Mice deficient in BACE1, the Alzheimers - secretase, have normal phenotype and abolished -amyloid generation. Nat. Neurosci. 4, 231232 (2001).
   Google Scholar
• Roberds SL, Anderson J, Basi G et al. BACE knockout mice are healthy despite lacking the primary -secretase activity in brain: implications for Alzheimers disease therapeutics. Hum. Mol. Genet. 10(12), 13171324 (2001).
   Google Scholar
• Kitazume S, Tachida Y, Oka R et al. Characterization of 2,6-sialyltransferase cleavage by Alzheimers -secretase (BACE1). J. Biol. Chem. 278(17), 1486514871 (2003).
   Google Scholar
• Hong L, Koelsch G, Lin X et al. Structure of the protease domain of memapsin 2 (- secretase) complexed with inhibitor. Science 290(5489), 150153 (2000).
   Google Scholar
• Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimers disease. Neurobiol. Aging 23(6), 10091016 (2002).
   Web of Science ®Google Scholar
• Gandy S, Almeida OP, Fonte J et al. Chemical andropause and amyloid- peptide. JAMA 285(17), 21952196 (2001).
   Web of Science ®Google Scholar
• Wolkowitz OM, Kramer JH, Reus VI et al. DHEA treatment of Alzheimers disease: a randomized, double-blind, placebocontrolled study. Neurology 60(7), 10711076 (2003).
   Web of Science ®Google Scholar
• Dartigues JF, Letenneur L. Genetic epidemiology of Alzheimers disease. Curr. Opin. Neurol. 13, 385389 (2000).
   Google Scholar
• Jarvik GP, Wijsman EM, Kukull WA et al. Interactions of apolipoprotein E genotype, total cholesterol level, age and sex in prediction of Alzheimers disease: a case-control study. Neurology 45, 10921096 (1995).
   Web of Science ®Google Scholar
• Holtzman DM. Apolipoprotein E isoformdependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimers disease. Proc. Natl Acad. Sci. 97, 28922897 (2000).
   Web of Science ®Google Scholar
• Sparks DL, Scheff SW, Hunsaker JC et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 8894 (1994).
   Web of Science ®Google Scholar
• Refolo LM, Malester B, LaFrancois J et al. Hypercholesterolemia accelerates the Alzheimers amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321331 (2000).
   Web of Science ®Google Scholar
• Kojro E. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the -secretase ADAM 10. Proc. Natl Acad. Sci. 98, 58155820 (2001).
   Google Scholar
• Fassbender K. Simvastatin strongly reduces levels of Alzheimers disease -amyloid peptides A 42 and A 40 in vitro and in vivo. Proc. Natl. Acad. Sci. 98, 58565861 (2001).
   Google Scholar
• Refolo LM, Pappolla MA, LaFrancois J et al. A cholesterol-lowering drug reduces -amyloid pathology in a transgenic mouse model of Alzheimers disease. Neurobiol. Dis. 8, 890899 (2001).
   Web of Science ®Google Scholar
• Puglielli L, Konopka G, Pack-Chung E et al. Acyl-coenzyme A: cholesterol acyltransferase (ACAT) modulates the generation of the amyloid peptide. Nat. Cell. Biol. 3, 905912 (2001).
   Web of Science ®Google Scholar
• Golde TE, Eckman CB. Cholesterol modulation as an emerging strategy for the treatment of Alzheimers disease. Drug. Discov. Today 20, 10491055 (2001).
   Google Scholar
• Jick H. Statins and the risk of dementia. Lancet 356, 16271631 (2000).
   Web of Science ®Google Scholar
• Shepherd J, Blauw G, Murphy M et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360 16231630 (2002).
   Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid- attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173177 (1999).
   Web of Science ®Google Scholar
• Games D, Adams D, Alessandrini R. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F - amyloid precursor protein. Nature 373, 523527 (1995).
   Google Scholar
• Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloid-peptide decreases cerebral amyloid burden in a mouse model of Alzheimers disease. Ann. Neurol. 48, 567579 (2000).
   Google Scholar
• Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimers disease. Nat. Med. 6, 916919 (2000).
   Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ et al. Peripheral antiA antibody alters CNS and plasma A clearance and decreases brain A burden in a mouse model of Alzheimers disease. Proc. Natl Acad. Sci. 98, 88508855 (2001).
   Web of Science ®Google Scholar
• Janus C, Pearson J, McLaurin J et al. A - peptide immunization reduces behavioural impairment and plaques in a model of Alzheimers disease. Nature 408, 979982(2000).
   Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE et al. A -peptide vaccination prevents memory loss in an animal model of Alzheimers disease. Nature 408, 982985 (2000).
   Web of Science ®Google Scholar
• Dodart JC, Bales KR, Gannon KS et al. Immunization reverses memory deficits without reducing brain A burden in Alzheimers disease model. Nat. Neurosci. 5, 452457 (2002).
   Web of Science ®Google Scholar
• Wyss-Coray T, Lin C, Yan F et al. TGFbeta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7, 612618 (2001).
   Google Scholar
• Poduslo JF, Curran GL. Amyloid- peptide as a vaccine for Alzheimers disease involves receptor-mediated transport at the bloodbrain barrier. Neuroreport 12(15), 31973200 (2001).
   Web of Science ®Google Scholar
• Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer -amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA 94(8), 41094112 (1997).
   Google Scholar
• Schenk D. Amyloid- immunotherapy for Alzheimers disease: the end of the beginning. Nat. Rev. Neurosci. 3(10), 824828 (2002).
   Google Scholar
• First demonstration of the efficacy of immunization with amyloid- in the animal model of Alzheimers disease.
   Google Scholar
• Hock C, Konietzko U, Papassotiropoulos A et al. Generation of antibodies specific for -amyloid by vaccination of patients with Alzheimers disease. Nat. Med. 11, 12701275 (2002).
   Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimers disease after immunization with amyloid- peptide: a case report. Nat. Med. 9(4), 448452 (2003).
   Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR et al. Antibodies against -amyloid slow cognitive decline in Alzheimers disease. Neuron 38, 547554 (2003).
   Web of Science ®Google Scholar
• Lemere CA, Spooner ET, Leverone JF et al. Amyloid- immunization in Alzheimers disease transgenic mouse models and wild type mice. Neurochem. Res. 28(7), 1017.1027 (2003).
   Web of Science ®Google Scholar
• Pfeifer M, Boncristiano S, Bondolfi L. Cerebral hemorrhage after passive antiA immunotherapy. Science 298, 1379 (2002).
   Google Scholar
• McLaurin J, Cecal R, Kierstead ME. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4.10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 11, 1263.1269 (2002).
   Google Scholar
• Sigurdsson E M, Scholtzova H, Mehta P D et al. Immunization with a nontoxic/ nonfibrillar amyloid- homologous peptide reduces Alzheimerfs disease associated pathology in transgenic mice. Am. J. Pathol. 159, 439.447 (2001).
   Google Scholar
• Frenkel D, Solomon B. Towards Alzheimerfs -amyloid vaccination. Biologicals 29, 243.247 (2001).
   Web of Science ®Google Scholar
• Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 498, 204.207 (2001).
   Web of Science ®Google Scholar
• Permanne B, Adessi C, Saborio GP et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimerfs disease by treatment with a - sheet breaker peptide. FASEB J. 16, 860.862 (2002).
   Web of Science ®Google Scholar
• Gervais F, Paquette J, Morisette C et al. A low molecular weight GAG mimetic compound reduces brain amyloid burden in hAPP transgenic mice. Proceedings 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva, Switzerland, Apr 3.6, 28C (2002).
   Google Scholar
• Bush AI. The metallobiology of Alzheimerfs disease. Trends Neurosci. 26(4), 207.214 (2003).
   Google Scholar
• Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of Alzheimerfs amyloid -peptide in insoluble aggregates and soluble complexes. Biochemistry 39(23), 7024.7031 (2000).
   Web of Science ®Google Scholar
• Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl Acad. Sci. USA 99(11), 7705.7710 (2002).
   Google Scholar
• Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimerfs disease transgenic mice. Neuron 30, 665.676 (2001).
   Web of Science ®Google Scholar
• Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254.259 (2002).
   Web of Science ®Google Scholar
• Iwata N, Tsubuki S, Takaki Y et al. Metabolic regulation of brain A by neprilysin. Science 292(5521), 1550.1552 (2001).
   Web of Science ®Google Scholar
• Marr RA, Rockenstein E, Mukherjee A et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23(6), 1992.1996 (2003).
   Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimerfs disease. Neurobiol. Aging 21, 383.421 (2000).
   PubMed Web of Science ®Google Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimerfs disease: a review of 17 epidemiologic studies. Neurology 47, 425.432 (1996).
   Google Scholar
• Int f Veld BA, Ruitenberg A, Hofman et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimerfs disease. N. Engl. J. Med. 345, 1515.1521 (2001).
   Google Scholar
• Addresses the important question of whether the nonsteroidal antiinflammatory drugs can influence the risk to develop Alzheimerfs disease.
   Google Scholar
• Ho L, Purohit D, Haroutunian V et al. Neuronal cyclooxygenase-2 expression in the hippocampal formation as a function of the clinical progression of Alzheimerfs disease. Arch. Neurol. 58, 487.492 (2001).
   Google Scholar
• Xiang Z, Ho L, Yemul S et al. COX-2 promotes amyloid plaque deposition in a mouse model of Alzheimerfs disease neuropathology. Gene Expression. 10, 271.278 (2002).
   Web of Science ®Google Scholar
• Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimerfs disease. J. Neurosci. 20, 5709.5714 (2000).
   Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Das Pet al. A subset of NSAIDs lower amyloidogenic A 42 independently of cyclooxygenase activity. Nature 414, 212.216 (2001).
   Google Scholar
• Tabet N, Feldman H. Indomethacin for treatment of AD Patients. Cochrane Database Syst. Rev. CD003673 (2002).
   Google Scholar
• Aisen PS, Schmeidler J, Pasinetti GM et al. Randomized pilot study of nimesulide treatment in Alzheimerfs disease. Neurology 58, 1050.1054 (2002).
   Web of Science ®Google Scholar
• Sainati SM, Ingram DM, Talwalker S et al. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimerfs disease. Proceedings of the 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy. 180, Stockholm, Sweden (2000).
   Google Scholar
• Block G, Norman B, Liu G et al. A clinical trial of rofecoxib, a selective COX-2 inhibitor, for the treatment of Alzheimerfs disease. Neurobiol. Aging 23, S73.S74 (2002).
   Google Scholar
• Aisen PS, Schafer K, Grundman M et al. Effects of rofecoxib or naproxen vs. placebo on Alzheimerfs disease progression. JAMA 289, 2819.2826 (2003).
   Google Scholar
• Aisen P, Davis KL, Berg JD et al. A randomized controlled trial of prednisone in Alzheimerfs disease. Neurology 54, 588.593 (2000).
   Web of Science ®Google Scholar
• Van Gool WA, Weinstein HC, Scheltens PK et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimerfs disease: an 18-month randomized, double-blind, placebocontrolled study. Lancet 358, 455.460 (2001).
   Google Scholar
• Lau LF, Schachter JB, Seymour PA, Sanner MA. Tau protein phosphorylation as a therapeutic target in Alzheimerfs disease. Curr. Top. Med. Chem. 2(4), 395.415 (2002).
   Google Scholar
• Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to - amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA 99(9), 6364.6369 (2002).
   Google Scholar
• Lewis J, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293(5534), 1487.1491 (2001).
   Web of Science ®Google Scholar
• Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A 42 fibrils. Science 293(5534), 1491.1495 (2001).
   Google Scholar
• Rogers JT, Randall JD, Eder PS. Alzheimerfs disease drug discovery targeted to the APP mRNA 5Luntranslated region. J. Mol. Neurosci. 19(1.2), 77.82 (2002)
   Google Scholar
• Pluchino S, Quattrini A, Brambilla E. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422(6933), 688.694(2003).
   Web of Science ®Google Scholar